Gabelli Funds LLC decreased its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI – Free Report) by 13.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 68,600 shares of the medical instruments supplier’s stock after selling 10,400 shares during the quarter. Gabelli Funds LLC’s holdings in ICU Medical were worth $9,787,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of ICUI. Covestor Ltd grew its holdings in shares of ICU Medical by 70.7% during the third quarter. Covestor Ltd now owns 570 shares of the medical instruments supplier’s stock worth $68,000 after purchasing an additional 236 shares in the last quarter. Strs Ohio grew its holdings in shares of ICU Medical by 60.0% during the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after purchasing an additional 300 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of ICU Medical by 11.6% during the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after purchasing an additional 101 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of ICU Medical during the second quarter worth about $177,000. Finally, Allegheny Financial Group purchased a new position in shares of ICU Medical during the fourth quarter worth about $214,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.
ICU Medical Stock Performance
Shares of ICUI stock opened at $123.66 on Wednesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34. ICU Medical, Inc. has a fifty-two week low of $107.00 and a fifty-two week high of $160.29. The stock has a 50 day moving average price of $125.48 and a two-hundred day moving average price of $138.48. The company has a market capitalization of $3.09 billion, a P/E ratio of 66.84, a PEG ratio of 1.77 and a beta of 0.74.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on the company. Piper Sandler cut their price objective on ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Jefferies Financial Group raised ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. KeyCorp cut their price objective on ICU Medical from $180.00 to $164.00 and set an “overweight” rating for the company in a report on Monday, April 27th. Weiss Ratings raised ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Finally, Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $169.00.
Read Our Latest Research Report on ICU Medical
Insider Buying and Selling
In related news, VP Virginia Ruth Sanzone sold 2,447 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the transaction, the vice president owned 19,460 shares in the company, valued at $2,414,596.80. This represents a 11.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the transaction, the director owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. This represents a 23.34% decrease in their position. The SEC filing for this sale provides additional information. 2.10% of the stock is owned by corporate insiders.
ICU Medical Profile
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Read More
- Five stocks we like better than ICU Medical
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Inc. (NASDAQ:ICUI – Free Report).
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.
